

Asiatic Laboratories Limited  
Statement of Changes in Equity (Un-audited)  
For the period ended 30 September 2024


(Amount in Taka)

Particulars	Ordinary Share Capital	Share Premium	Revaluation Surplus	Retained Earnings	Total
Balance as at July 1, 2024	1,223,934,550	578,227,731	1,624,138,128	3,009,259,939	6,435,560,348
Adjustment of depreciation for Revaluation Surplus	-	-	(1,038,215)	1,038,215	-
Adjustment of deferred tax on depreciation for Revaluation Surplus (22.50%)	-	-	-	233,598	233,598
Net profit for the year transferred from Statement of Profit or Loss & Other Comprehensive Income.	-	-	-	29,623,772	29,623,772
Balance as at September 30, 2024	1,223,934,550	578,227,731	1,623,099,913	3,040,155,524	6,465,417,718

For the period ended 30 September 2023

(Amount in Taka)

Particulars	Ordinary Share Capital	Share Money Deposit (IPO Fund)	Revaluation Surplus	Retained Earnings	Total
Balance as at July 1, 2023	878,480,000	431,818,180	1,628,560,575	2,725,421,015	5,664,279,770
Adjustment of depreciation for Revaluation Surplus	-	-	(1,094,362)	1,094,362	-
Adjustment of deferred tax on depreciation for Revaluation Surplus (22.50%)	-	-	-	246,232	246,232
Net profit for the year transferred from Statement of Profit or Loss & Other Comprehensive Income.	-	-	-	88,463,367	88,463,367
Balance as at September 30, 2023	878,480,000	431,818,180	1,627,466,212	2,815,224,976	5,752,989,368

 Chief Financial Officer    
  Company Secretary    
  Director    
  Managing Director    
  Chairman

Place: Dhaka  
Dated: 30 November 2024